Why the study?
To address the metabolic instability of a previously discovered brain-penetrant HDAC6 inhibitor through metabolic site identification and structural optimization.
Compound 8k is a metabolically stable, highly selective HDAC6 inhibitor that demonstrates neuroprotective efficacy by reducing cerebral infarction in a rat model of ischemic stroke.
May advance HDAC6 inhibition for CNS disorders; leaves open clinical translation of optimized inhibitors.
Inhibition of histone deacetylase 6 (HDAC6) has become a promising therapeutic strategy for central nervous system diseases. To address the metabolic instability of our previously discovered brain-penetrant HDAC6 inhibitor 5, herein the identification of metabolic sites and structural optimization based on 5 were carried out. The most potent compound, 8k, potently and selectively inhibited HDAC6 (IC 50 = 4.0 nM; >176-fold selectivity) and exhibited a 2-fold longer half-life in rat liver microsomes ( T 1/2 = 29.49 min) than 5 . It stabilized the HDAC6 complex in silico and increased the level of acetylated α-tubulin in SH-SY5Y cells. In vivo, 8k significantly reduced cerebral infarction (from 32.87% to 13.13%) in the rat MCAO model. These results demonstrate that 8k is a metabolically stable, highly selective HDAC6 inhibitor with compelling neuroprotective efficacy, warranting its further development for ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: